IP Library Granted Patent US 7,576,127
Granted Patent B2
US 7,576,127 · App. 11/507,968 · Granted Aug 18, 2009

Aromatic prodrugs of propofol, compositions and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,576,127
App. No.
11/507,968
Granted
Aug 18, 2009
Kind
B2
Abstract

Prodrugs of propofol, methods of making prodrugs of propofol, pharmaceutical compositions of prodrugs of propofol and methods of using prodrugs of propofol and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting are disclosed herein.

Claims (29)

1. A method of treating migraine in a patient comprising administering to a patient in need thereof a pharmaceutical composition comprising a compound of Formula (I):

or a pharmaceutically acceptable salt or N-oxide thereof, and a pharmaceutically acceptable vehicle, wherein:

n is 0;

Y is selected from the group consisting of a bond and O;

A is CR 4 ;

B is CR 5 ;

D is CR 6 ;

E is CR 7 ;

G is CR 8 ;

R 4 is selected from the group consisting of hydrogen and —W[C(O)] k Z(CR 9 R 10 ) r CO 2 R 11 ;

R 5 is selected from the group consisting of hydrogen and —W[C(O)] k Z(CR 9 R 10 ) r CO 2 R 11 ;

R 6 is selected from the group consisting of hydrogen and —W[C(O)] k Z(CR 9 R 10 ) r CO 2 R 11 ;

R 7 is selected from the group consisting of hydrogen and —W[C(O)] k Z(CR 9 R 10 ) r CO 2 R 11 ;

R 8 is selected from the group consisting of hydrogen and —W[C(O)] k Z(CR 9 R 10 ) r CO 2 R 11 ;

W is a bond;

Z is NR 17 ;

k is 1;

r is 1, 2 or 3;

each of R 9 ,R 10 , and R 11 is hydrogen;

R 17 is hydrogen;

R 18 is hydrogen, alkyl, substituted alkyl, alkoxycarbonyl, aryl, substituted aryl, arylalkyl, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, heteroaryl, substituted heteroaryl and heteroarylalkyl;

with the proviso that:

one and only one of R 4 ,R 5 ,R 6 ,R 7 or R 8 is —W[C(O)] k Z(CR 9 R 10 ) r CO 2 R 11 .

2. The method of claim 1 , wherein Y is a bond.

3. The method of claim 2 , wherein the compound is 3-{[2-[2,6-bis(isopropyl)phenoxycarbonyl]-benzoyl]amino}propanoic acid or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein Y is O.

5. The method of claim 4 , wherein the compound is 3-{[2-[2,6-bis(isopropyl)phenoxycarbonyloxy]benzoyl]amino}propanoic acid or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 , wherein the pharmaceutical composition is an oral formulation.

7. The method of claim 6 , wherein the oral formulation is a sustained release oral formulation.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Oct 20, 2021
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: ARBOR PHARMACEUTICALS, LLC; WILSHIRE PHARMACEUTICALS, INC.; XENOPORT, INC.
Reel/Frame 057880/0174 →
SECURITY INTEREST Recorded Jul 6, 2016
From: ARBOR PHARMACEUTICALS, LLC; XENOPORT, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 039266/0345 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2008
From: GALLOP, MARK A.; XU, FENG
To: XENOPORT, INC.
Reel/Frame 021818/0591 →